Endoprosthetic proximal femur replacement: Metastatic versus primary tumors

Few studies have examined the impact of underlying diagnosis on the functional and oncologic outcomes following endoprosthetic proximal femur replacement (PFR). We performed a retrospective review of 61 consecutive cemented bipolar PFR in 59 patients for treatment neoplastic lesions with a minimum follow-up of 24 months. Twenty-two patients had primary bone tumors and 39 had metastatic disease. Average follow-up for the 30 surviving patients was 55.4 months and the mean postoperative survival for the 29 patients who died was 12.2 months. Patients with primary tumors demonstrated significantly better functional outcomes than those with metastatic disease, with mean Musculoskeletat Tumor Society functional scores of 80.2 and 66.8%, respectively (p = 0.0002). Age correlated inversely with functional scores (r = -0.48; p = 0.0002), white femoral. resection length did not. Preoperative pathologic fracture did not appear to adversely impact final functional outcomes. The Kaptan-Meier 5-year implant survival estimate was 92.5%, with aseptic loosening as the endpoint. Both functional results and survival are increased for primary tumors versus metastatic disease following PFR. However, PFR results in excellent, local disease control, reliable pain relief and good functional results in both groups, with prosthesis survival exceeding that of the patient in many cases. Published by Elsevier Ltd.